Xenetic Biosciences, Inc.
XBIO Healthcare Biotechnology
Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 8.89% and free cash flow fell 128.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow XBIO
Xenetic Biosciences, Inc. (XBIO) EV/Sales
As of 16 October 2026, Xenetic Biosciences, Inc. (XBIO) trades at a EV/Sales of −0.2×. Over the past ten years it has ranged from −7.0× (March 2022) to 51.2× (July 2021); the current reading is higher than 29% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.0× | — |
| FY2024 | 0.4× | — |
| FY2023 | −0.9× | — |
| FY2022 | −4.5× | — |
| FY2021 | −3.3× | — |
| FY2020 | 6.1× | — |
| FY2019 | −0.6× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.4× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | −1.0× | — |
| Sep 2025 | 0.6× | (33.85%) |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AZTR Azitra, Inc. compare | −9.3× |
| LGVN Longeveron Inc. compare | −4.2× |
| XBIO Xenetic Biosciences, Inc. | −0.2× |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | n/m |
| PCSA Heatwurx Inc. compare | 45.3× |
| ADTX Aditxt, Inc. compare | 73.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)